Showing results (6081-6090 of 10,080) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|August 26, 2011
Experimental strategies in autoimmunity: antagonists of cytokines and their receptors, nanocarriers, inhibitors of immunoproteasome, leukocyte migration and protein kinasesAlessandra Fierabracci, Emira AyroldiCurrent Pharmaceutical Design|August 26, 2011
Manipulating thymic apoptosis for future therapy of autoimmune diseasesDomenico V Delfino, Nicola Pozzesi, Sara Pierangeli, et al.Current Pharmaceutical Design|August 26, 2011
Novel therapeutic approaches to autoimmune demyelinating disordersLara Sanvito, Cris S Constantinescu, Bruno GranCurrent Pharmaceutical Design|September 17, 2011
Cell therapy for the treatment of chronic ischemic heart diseaseSander F Rodrigo, Jan van Ramshorst, Saskia L M A Beeres, et al.Current Pharmaceutical Design|September 17, 2011
Endothelial progenitor cells: quod erat demonstrandum?Dirk StrunkCurrent Pharmaceutical Design|September 10, 2011
Gene therapy for Parkinson's and Alzheimer's diseases: from the bench to clinical trialsRui Jorge Nobre, Luís Pereira de AlmeidaCurrent Pharmaceutical Design|June 30, 2011
Urokinase receptor (uPAR) ligand based recombinant toxins for human cancer therapyMaddalena de Virgilio, Franco SilvestrisCurrent Pharmaceutical Design|June 30, 2011
Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinicAndrew P Mazar, Richard W Ahn, Thomas V O'HalloranCurrent Pharmaceutical Design|June 30, 2011
The urokinase receptor system, a key regulator at the intersection between inflammation, immunity, and coagulationMario Del Rosso, Francesca Margheri, Simona Serratì, et al.Current Pharmaceutical Design|June 30, 2011
Clinical applications of the urokinase receptor (uPAR) for cancer patientsMartin C Boonstra, Hein W Verspaget, Sjam Ganesh, et al.Pageof 1,008